Tag: RSH
Respiri raises $12.5 million to commercialise wheezo asthma device
eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end.
...
Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost
Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China, which is expected to “significantly improve” productio...
Respiri unveils promising wheezo clinical study results
Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting ...
Respiri teams up with Carlton Football Club to promote wheezo device
A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, comme...
Respiri signs referral agreement with APA to proliferate wheezo in Australia
eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the A...
Respiri partners with Australian Patients Association for wheezo study
eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma suff...
eHealth SaaS provider Respiri targets $6-8m revenue for 2021
eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated...
Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip
Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy now pay later provider Zip Co Ltd (ASX: Z1P).
Respiri c...
Respiri secures global sales and distribution agreement for wheezo asthma monitoring device
Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the sales and distribution of Respiri’s wheezo asthma product...
Respiri partners with UK data research centre in preparation for Wheezo’s EU launch
eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its proprietary Wheezo devices into a new data research centre i...
Respiri grows wheezo market potential through agreement with the Pharmacy Guild of Australia
Respiri (ASX: RSH) has collared a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online pharmacist course on optimising asthma patient management including th...
Shareholders back Respiri in heavily oversubscribed share purchase plan
Respiri (ASX: RSH) has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase plan.
The company launched the share purchase plan l...
Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients
Respiratory health management company Respiri (ASX: RSH) has entered into commercial discussions with Australian start-up Practice Innovators International Pte Ltd with a view to launching an integrat...
Respiri expands wheezo into telehealth market with Phenix partnership
Respiri (ASX: RSH) has expanded the market for its wheezo technology after announcing a partnership with Phenix Health.
The parties have inked a joint development agreement which will involve integ...
Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China
Respiratory focused SaaS company Respiri (ASX: RSH) has experienced inbound demand for its wheezo technology from three Chinese hospitals relating to monitoring patients with coronavirus COVID19...
Respiri’s Wheezo product approved for sale following CE Mark and TGA registration
Healthcare technology developer Respiri (ASX: RSH) has revealed that the company has received the highly coveted CE Mark and TGA approval to list its Wheezo product on the Australian Therapeutics Good...
Appointment of professor Bruce Thompson provides Respiri clinical credibility
Bruce Thompson has been appointed as chair of Respiri’s (ASX: RSH) Australian medical and scientific Advisory board and product portfolio development lead.
Bruce Thompson is Professor of Allergy, I...
Respiri appoints SRX Global to manufacture wheeze and asthma sensor
Respiri (ASX: RSH) has ticked off another key milestone – a manufacturing agreement with SRX Global, to produce its next generation breath and asthma wheeze detection sensor.
The sensor is the hard...
Respiri’s wheeze monitoring device to improve asthma management
Healthcare technology developer Respiri (ASX: RSH) is in the final stages of commercialising its asthma monitoring product called AirSonea.
It will be a major boost for asthma sufferers worldwide, ...
